Verified peer comparison

PFE vs JNJ

Pfizer Inc. compared with Johnson & Johnson. This page compares both source-verified company profiles and does not introduce an unverified price target.

PFE

Pfizer Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

JNJ

Johnson & Johnson

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

PFE: Pharmaceuticals

JNJ: Pharmaceuticals

Upside lens

PFE: Commercial growth and pipeline progress from the Seagen portfolio can deepen Pfizer's oncology position and offset maturing products. Successful late-stage readouts, regulatory approvals and launch execution can create new growth sources across oncology, vaccines and specialty care. Manufacturing and operating cost programs can improve productivity and create capacity to fund pipeline investment and debt reduction.

JNJ: Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products. Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth. Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.

Risk lens

PFE: Loss of exclusivity for major products can cause abrupt revenue erosion if launches and acquired products do not scale quickly enough. Trial failures, safety findings, approval delays or reimbursement restrictions can eliminate expected pipeline value after substantial investment. Realizing returns from acquisitions requires successful integration and commercialization while servicing debt and managing acquired intangible assets.

JNJ: Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts. Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines. Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.